Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to the United States' request for sensitive biological samples.
This rejection came to light following a internal memorandum from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official representative later clarified that the United States was demanding access to genetic material for scientific study and commercial gain while was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for more dialogue to reach a deal suitable to both sides so the nation's vital HIV programme can be sustained.
Broader Implications
This development comes after a similar case in neighbouring Kenya, where a high court blocked a related deal with the US following concerns were raised about the security of Kenyans' medical information.
After returning to office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance transparency and responsibility.
Based on statements, 16 African countries have so far signed these new agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data over an extended period, with no corresponding guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"In essence, our country would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our people if a future disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its push of one-on-one deals were upending frameworks already established via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This framework is intended to guarantee that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We encourage continued discussions with our US partners on how subsequent co-operation could be arranged in a way that honours the independence and interests of both nations."
Medical Community Response
Medical experts stated it recognised the government's concerns, but recommended that talks need to persist since a large portion of the country's HIV programmes relied on international support.
"In cases where specific concerns arise, such as those involving data governance or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," the group said.
The halted deal highlights the continuing challenges between accepting vital international aid and safeguarding local interests in an increasingly data-driven world.